CN114766677A - Application of lactobacillus rhamnosus LRa05 in preparing preparation for improving irritable bowel syndrome - Google Patents
Application of lactobacillus rhamnosus LRa05 in preparing preparation for improving irritable bowel syndrome Download PDFInfo
- Publication number
- CN114766677A CN114766677A CN202210408975.2A CN202210408975A CN114766677A CN 114766677 A CN114766677 A CN 114766677A CN 202210408975 A CN202210408975 A CN 202210408975A CN 114766677 A CN114766677 A CN 114766677A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- lra05
- oligosaccharide
- parts
- rhamnosus lra05
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 108
- 208000002551 irritable bowel syndrome Diseases 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 10
- 235000013361 beverage Nutrition 0.000 claims description 43
- 239000007787 solid Substances 0.000 claims description 40
- 229920001202 Inulin Polymers 0.000 claims description 18
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 18
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 18
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 18
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 18
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 18
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 18
- 229940029339 inulin Drugs 0.000 claims description 18
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- 239000003223 protective agent Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000008176 lyophilized powder Substances 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 241000792859 Enema Species 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 239000007920 enema Substances 0.000 claims description 4
- 229940095399 enema Drugs 0.000 claims description 4
- 230000003068 static effect Effects 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 238000009630 liquid culture Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 238000009629 microbiological culture Methods 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 20
- 239000002158 endotoxin Substances 0.000 abstract description 11
- 230000000770 proinflammatory effect Effects 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 230000036542 oxidative stress Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 12
- 235000013406 prebiotics Nutrition 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- -1 isomaltose oligosaccharide Chemical class 0.000 description 11
- 229920001542 oligosaccharide Polymers 0.000 description 11
- 239000006041 probiotic Substances 0.000 description 11
- 235000018291 probiotics Nutrition 0.000 description 11
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 206010000060 Abdominal distension Diseases 0.000 description 6
- 240000006024 Lactobacillus plantarum Species 0.000 description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 6
- 230000013872 defecation Effects 0.000 description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 description 4
- 241000192142 Proteobacteria Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 244000199866 Lactobacillus casei Species 0.000 description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 description 3
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical group N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 229940017800 lactobacillus casei Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 241000606750 Actinobacillus Species 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- 241000605059 Bacteroidetes Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000191998 Pediococcus acidilactici Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides application of lactobacillus rhamnosus LRa05 in preparing a preparation for improving irritable bowel syndrome. The Lactobacillus rhamnosus LRa05 freeze-dried powder provided by the invention has obvious curative effect on irritable bowel syndrome, can reduce serum endotoxin, reduce proinflammatory factors, increase the level of the anti-inflammatory factors, relieve oxidative stress and adjust intestinal flora disturbance, thereby healthizing intestinal flora. The Lactobacillus rhamnosus LRa05 freeze-dried powder product provided by the invention is simple to prepare and suitable for mass production, and has the characteristics of simple treatment, high remission rate, no toxic or side effect and the like as an auxiliary medicine for IBS, and has high practicability.
Description
Technical Field
The invention belongs to the field of nutritional health-care foods, and particularly relates to an application of lactobacillus rhamnosus LRa05 in preparation of a preparation for improving irritable bowel syndrome.
Background
Irritable Bowel Syndrome (IBS) is one of the most common functional gastrointestinal disorders, and epidemiological studies around the world have reported that IBS is a frequently occurring disease worldwide. The prevalence rate of the population in western countries reaches 10% -20%, and epidemiological investigation according to the Roman II standard in China shows that the prevalence rate of IBS in community population is 5.7%, wherein 22% of IBS is treated once due to IBS symptoms. IBS is a disease in which abdominal pain, abdominal distension, or abdominal discomfort is the main symptom, and is associated with defecation or accompanied by a change in defecation habits such as frequency and/or stool characteristics. Although IBS is not life threatening, it is one of the most common causes affecting the quality of life of patients, and it is of great importance to find an effective treatment for IBS. It is widely believed that the onset of IBS is related to various factors such as intestinal flora, intestinal barrier function, intestinal immune function, and visceral sensitivity.
The human gastrointestinal tract is populated with trillions of microorganisms, called gut flora, a second set of genomic information from the human body, other than chromosomes. With the continuous update of DNA sequencing technology, the way for people to research intestinal flora is more and more convenient, and the research on the intestinal flora is deeper and deeper. The intestinal flora not only maintains the balance of the physiological activities of human bodies, but also is influenced by various factors. When the environment in the organism changes, the composition and distribution of intestinal flora will change, otherwise, the imbalance of intestinal flora caused by the change of factors such as environment can also cause a series of physiological and pathological changes of the organism. The research finds that the intestinal flora of IBS patients has obvious difference in species and quantity compared with healthy people, for example, the quantity of enterobacteria, staphylococcus and the like in the feces of the IBS patients is increased, the quantity of lactobacillus and bifidobacterium is reduced, and the symptoms of abdominal distension, diarrhea and the like of the patients are related to the change of the flora. From the perspective of adjusting intestinal flora, the adoption of probiotics to treat IBS by adjusting normal intestinal flora is a relatively safe and effective measure, but the treatment effect on IBS is different due to the fact that probiotics are various in types, so that an efficient and safe probiotic treatment scheme is significant.
CN112654358A discloses a combination of lactic acid bacteria for the relief of irritable bowel syndrome and for the relief of other gastrointestinal disorders, said compositions and methods relating to the use of live lactobacillus bacteria, in particular live lactobacillus acidophilus, live lactobacillus casei and live lactobacillus rhamnosus for the relief of undesired gastrointestinal health problems, such as Irritable Bowel Syndrome (IBS), abdominal pain, abdominal discomfort, abdominal distension, watery stools and constipation, but the lactobacillus rhamnosus with the deposit number CNCM I-3990 disclosed in this application has a limited capacity for the relief of irritable bowel syndrome and therefore needs to comply with live lactobacillus acidophilus and live lactobacillus casei for the purpose of relieving irritable bowel syndrome and for the relief of other gastrointestinal disorders.
CN113854360A discloses a probiotic freeze-dried powder and a preparation method thereof. The probiotic freeze-dried powder is rich in various prebiotics, various dietary fibers and various vitamins, various strains are selected, and a finished product is obtained by adopting a multilayer embedding technology. The finished product contains more than 18000 hundred million CFU. The probiotic comprises lactobacillus plantarum, bifidobacterium and pediococcus acidilactici; the lactobacillus plantarum comprises one or more of lactobacillus plantarum Lp90, lactobacillus plantarum N13, lactobacillus plantarum CN2018, lactobacillus plantarum CW006, lactobacillus reuteri LR08 and lactobacillus rhamnosus LRa 05. The prebiotics component in the formula of the freeze-dried powder cannot achieve the purpose of promoting the lactobacillus rhamnosus LRa05 in the intestinal tract.
Therefore, there is a need to develop a product capable of improving irritable bowel syndrome better.
Disclosure of Invention
In view of the defects of the prior art, the invention aims to provide the application of lactobacillus rhamnosus LRa05 in preparing a preparation for improving irritable bowel syndrome. The invention provides a probiotic with a significant improvement effect on IBS, and overcomes some defects in the field of IBS treatment by probiotics.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the invention provides a use of lactobacillus rhamnosus LRa05 in the preparation of a preparation for improving irritable bowel syndrome.
In the invention, the Lactobacillus rhamnosus LRa05 is Lactobacillus rhamnosus LRa05, is preserved in China general microbiological culture Collection center (CGMCC), has the preservation time of 2020, 7 and 20 days, has the preservation number of CGMCC No.1.12734 and the address of: xilu No.1 Hospital No. 3, Beijing, Chaoyang, Beicheng.
The Lactobacillus rhamnosus LRa05 freeze-dried powder provided by the invention has a remarkable curative effect on irritable bowel syndrome, can reduce serum endotoxin, reduce proinflammatory factors, increase the level of anti-inflammatory factors, relieve oxidative stress and adjust intestinal flora disorder, so that intestinal flora is healthful, and the Lactobacillus rhamnosus LRa05 freeze-dried powder provided by the invention is simple to prepare and suitable for mass production, has the characteristics of simplicity in treatment, high remission rate, no toxic or side effect and the like as an auxiliary medicine for IBS, and is high in practicability.
The isolation screening process and the identification result of the said Lactobacillus rhamnosus LRa05 strain are described in patent application No. 202010793756.1.
In the present invention, the formulation includes an oral drug and/or food.
Preferably, the dosage form of the oral medicine comprises any one of suppository, powder, capsule, powder, solution, emulsion, enema, gel or tablet.
Preferably, the food comprises any one of a solid beverage, fermented milk or fermented fruit and vegetable or a combination of at least two of the above.
In a second aspect, the invention provides a solid beverage containing lactobacillus rhamnosus LRa05, which comprises the following components in percentage by weight: freeze-dried powder containing lactobacillus rhamnosus LRa05, fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomalto-oligosaccharide and inulin.
In the invention, the fructo-oligosaccharide, the xylo-oligosaccharide, the galacto-oligosaccharide, the isomaltose oligosaccharide and the inulin are mutually matched, so that the synergistic effect is achieved, the multiplication of Lactobacillus rhamnosus (Lactobacillus rhamnosus) LRa05 in intestinal tracts can be further promoted, and a product obtained by combining the two components has a more excellent IBS (IBS) improving effect.
Wherein, fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomalto-oligosaccharide and inulin are all commercially available products.
In the invention, the solid beverage containing lactobacillus rhamnosus LRa05 comprises the following components in parts by mass: 0.1-10 parts of freeze-dried powder containing lactobacillus rhamnosus LRa05, 10-20 parts of fructo-oligosaccharide, 10-20 parts of xylo-oligosaccharide, 10-15 parts of galacto-oligosaccharide, 10-15 parts of isomalto-oligosaccharide and 10-20 parts of inulin.
In the solid beverage containing lactobacillus rhamnosus LRa05, the content of the freeze-dried powder containing lactobacillus rhamnosus LRa05 is 0.1-10 parts, such as 0.1 part, 0.5 part, 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts and the like.
The content of the fructo-oligosaccharide in the solid beverage containing the lactobacillus rhamnosus LRa05 is 10-20 parts, such as 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts and the like.
The solid beverage containing lactobacillus rhamnosus LRa05 has xylo-oligosaccharide content of 10-20 parts, such as 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, etc.
The solid beverage containing lactobacillus rhamnosus LRa05 has galacto-oligosaccharide content of 10-15 parts, such as 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, etc.
The solid beverage containing lactobacillus rhamnosus LRa05 has isomaltose hypgather content of 10-15 parts, such as 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, etc.
The solid beverage containing lactobacillus rhamnosus LRa05 has inulin content of 10-20 parts, such as 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, etc.
In the invention, the number of viable bacteria in the freeze-dried powder containing lactobacillus rhamnosus LRa05 is (1-3) multiplied by 1011CFU/g, for example, may be 1X 1011CFU/g、1.5×1011CFU/g、2×1011CFU/g、2.5×1011CFU/g、3×1011CFU/g, and the like.
In the invention, the freeze-dried powder containing lactobacillus rhamnosus LRa05 is prepared by the following preparation method:
(a) activating the strain of lactobacillus rhamnosus LRa05, culturing, and collecting thallus;
(b) and (b) mixing the thallus obtained in the step (a) with a protective agent, and carrying out freeze drying to obtain the freeze-dried powder containing the lactobacillus rhamnosus LRa 05.
Preferably, in the step (a), the specific steps of the activation are: inoculating Lactobacillus rhamnosus LRa05 into MRS liquid culture medium, standing for culture, and activating for 2 generations.
Preferably, the lactobacillus rhamnosus LRa05 is inoculated in an amount of 1-3 wt%, which may be, for example, 1 wt%, 1.5 wt%, 2 wt%, 2.5 wt%, 3 wt%, etc.
Preferably, the temperature of the static culture is 32-37 ℃, for example, 32 ℃, 33 ℃, 34 ℃, 35 ℃, 36 ℃, 37 ℃ and the like, and the time of the static culture is 16-20h, for example, 16h, 17h, 18h, 19h, 20h and the like.
Preferably, in step (a), the culturing specifically comprises: and inoculating the activated seeds into a fermentation tank, and culturing to obtain a bacterial liquid.
Preferably, the amount of inoculated seed after activation is 1-3 wt%, and may be, for example, 1 wt%, 1.5 wt%, 2 wt%, 2.5 wt%, 3 wt%, etc.
Preferably, the temperature of the culture is 32-37 ℃, for example, 32 ℃, 33 ℃, 34 ℃, 35 ℃, 36 ℃, 37 ℃ and the like, and the time of the culture is 10-15h, for example, 10h, 11h, 12h, 13h, 14h, 15h and the like.
Preferably, the pH of the bacterial liquid to be controlled during the culture is 5.5 to 6.5, and may be, for example, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5 or the like.
Preferably, in the step (a), the step of collecting the bacterial cells comprises the following steps: centrifuging the bacterial liquid, removing supernatant, and collecting bacterial mud.
Preferably, the rotation speed of the centrifugation is 6000-8000r/min, such as 6000r/min, 6500r/min, 7000r/min, 7500r/min, 8000r/min, etc., and the time of the centrifugation is 10-15min, such as 10min, 11min, 12min, 13min, 14min, 15min, etc.
In step (b), the mass ratio of the cell to the protective agent is preferably (0.5-2):1, and may be, for example, 0.5:1, 0.6:1, 0.8:1, 1:1, 1.2:1, 1.4:1, 1.6:1, 1.8:1, 2:1, or the like.
Preferably, the protective agent consists of trehalose, maltodextrin and sucrose;
preferably, the mass ratio of the trehalose to the maltodextrin to the sucrose is (20-30) to (5-15) to (1-3);
wherein "20-30" can be, for example, 20, 22, 24, 26, 28, 30, etc.;
wherein "5 to 15" may be, for example, 5, 7, 9, 11, 13, 15, etc.;
here, "1 to 3" may be, for example, 1, 1.5, 2, 2.5, 3, etc.
In a third aspect, the present invention provides a preparation method of the solid beverage containing lactobacillus rhamnosus LRa05 according to the second aspect, wherein the preparation method comprises the following steps:
and mixing the freeze-dried powder containing the lactobacillus rhamnosus LRa05, fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomaltose oligosaccharide and inulin to obtain the solid beverage containing the lactobacillus rhamnosus LRa 05.
Preferably, the mixing speed is 10-30r/min, such as 10r/min, 15r/min, 20r/min, 25r/min, 30r/min, etc., the mixing temperature is 20-30 ℃, such as 20 ℃, 22 ℃, 24 ℃, 26 ℃, 28 ℃, 30 ℃, etc., and the mixing time is 20-40min, such as 20min, 25min, 30min, 35min, 40min, etc.
Compared with the prior art, the invention has the following beneficial effects:
(1) the Lactobacillus rhamnosus LRa05 freeze-dried powder provided by the invention has a remarkable curative effect on irritable bowel syndrome, can reduce serum endotoxin, reduce proinflammatory factors, increase the level of anti-inflammatory factors, relieve oxidative stress and adjust intestinal flora disorder, so that intestinal flora is healthful, and the Lactobacillus rhamnosus LRa05 freeze-dried powder product provided by the invention is simple to prepare and suitable for mass production, has the characteristics of simple treatment, high remission rate, no toxic or side effect and the like as an auxiliary medicine for IBS, and has high practicability;
(2) the prebiotics fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomaltose oligosaccharide and inulin can promote the proliferation of Lactobacillus rhamnosus LRa05 in intestinal tracts, the combination of the prebiotics fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomaltose oligosaccharide and inulin with Lactobacillus rhamnosus LRa05 improves the colonization rate and the survival rate of exogenous probiotics on intestinal tracts, and a product obtained by combining the two components has more excellent IBS improving effect.
Drawings
FIG. 1 is a graph of the change in the level of lipopolysaccharide between groups.
FIG. 2 is a graph of changes in TNF levels between groups.
FIG. 3 is a graph of the change in the level of proinflammatory factor interleukin 6 between groups.
FIG. 4 is a graph of the change in the level of proinflammatory factor interleukin 8 between groups.
FIG. 5 is a graph showing the change in IL-10 levels between groups.
FIG. 6 is a graph of the change in malondialdehyde levels between groups.
FIG. 7 is a graph showing the change in levels of superoxide dismutase between groups.
FIG. 8 is a graph showing the change in glutathione levels between groups.
FIG. 9 is a graph showing the structural change of the flora between groups at the phylum level.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Preparation example
The preparation example provides freeze-dried powder containing lactobacillus rhamnosus LRa05, and the freeze-dried powder containing lactobacillus rhamnosus LRa05 is prepared by the following preparation method:
(a) inoculating Lactobacillus rhamnosus (Lactobacillus rhamnosus) LRa05 preserved in glycerin tube into MRS liquid culture medium at a ratio of 2%, standing and culturing at 37 deg.C for 18h, and activating for 2 generations; inoculating the activated seed at 2% into a fermenter, culturing at 37 deg.C for 12h, controlling pH to 5.5, centrifuging the bacterial liquid 7000r/min for 12min, discarding supernatant, collecting bacterial mud,
(b) adding a mixed protective agent consisting of trehalose, maltodextrin and sucrose into the obtained bacterial sludge, wherein the protective agent comprises 25% of trehalose, 10% of maltodextrin, 2% of sucrose and 63% of pure water, the mass ratio of the protective agent to the bacterial sludge is 1:1, and then performing vacuum freeze drying to prepare freeze-dried powder, wherein the viable count of the freeze-dried powder LRa05 of Lactobacillus rhamnosus (Lactobacillus rhamnosus) reaches 2 x 1011CFU/g。
Example 1
Research on the improvement effect of Lactobacillus rhamnosus LRa05 lyophilized powder on IBS
Firstly, constructing an animal model:
selecting 72 SD rats with the weight of 200-220g for females in 6-8 weeks, adaptively feeding the SD rats for 1 week after purchase, wherein the light and shade period is 12 hours, the room temperature is controlled to be 20-25 ℃, the SD rats are freely fed with food and water, and the rat feed comprises protein, corn oil, carbohydrate and the like. 72 SD rats were evenly divided into a normal group, an IBS group and an LRa05 group, each group consisting of 24 rats, according to the physical and physical conditions, and animal models were constructed for the IBS group and the LRa05 group of rats by using a chemical stimulation method. The specific method comprises the following steps: caulis et folium Brassicae JunceaeDiluting the oil with corn oil at 5% concentration, sucking 0.5mL with 5cm length trocar, performing enema after defecating in rats every morning, injecting into rectum of rats at 5cm length for 1/d, performing continuous enema for 2 weeks, simultaneously, administering Lactobacillus rhamnosus LRa05 lyophilized powder solution (lyophilized powder dissolved in physiological saline) to LRa05 group, and performing intragastric administration for each rat at 1 × 10 per day to obtain lyophilized powder solution9CFU), whereas normal group and IBS group were given physiological saline (0.1mL/10 g).
(II) general condition checking:
observing the model of each group of rats and the overall state of Lactobacillus rhamnosus (LRa 05) before and after intervention, such as drinking water, diet, body mass, stool, death and the like, calculating Disease Activity Index (DAI), wherein the specific test results are shown in the following table 1:
TABLE 1
As shown in Table 1, the rats in the normal group had good overall status, high mobility and no diarrhea; after the rats in the IBS group are modeled, the diet, the water intake and the activity are reduced, the hair color is sparse and yellow, the spirit is listened, diarrhea with different degrees is generated, the excrement is yellow and thin, the water content of the excrement is obviously increased (P <0.01), and the DAI is obviously improved (P < 0.01); the overall state of the rats in the LRa05 group is improved, the activity is obviously increased, the diarrhea is obviously improved (P is less than 0.01), the water content of the excrement is reduced, and the DAI is obviously reduced. No death occurred during the period.
(III) detection of blood indexes:
the blood samples collected in the rat inferior vena cava blood sampling are centrifuged for 20min at 4000rpm, serum is separated, and the level of serum Lipopolysaccharide (LPS) of each group of rats is respectively detected by an ELISA (enzyme-linked immunosorbent assay), wherein the LPS is a component of gram-negative bacteria cell walls, is also called endotoxin, and is the most important pathogenic substance. In addition, the level changes of tumor necrosis factor (TNF-alpha), proinflammatory factor interleukin 6(IL-6), interleukin 8(IL-8) and anti-inflammatory factor interleukin 10(IL-10) are analyzed, which are important parts in the inflammatory response of irritable bowel syndrome, and the operation is carried out according to the ELISA kit specification.
As a result, as shown in fig. 1, the LPS level in the IBS group was significantly increased (p <0.001) compared to the normal group, and the LPS level was significantly decreased (p <0.001) after Lactobacillus rhamnosus LRa05 drying, which indicates that Lactobacillus rhamnosus LRa05 is effective in improving the accumulation of serum endotoxin under irritable bowel syndrome.
As a result, as shown in FIGS. 2 to 5, the levels of tumor necrosis factor TNF-alpha, proinflammatory factor IL-6 and proinflammatory factor IL-8 are significantly increased (p <0.001), the level of anti-inflammatory factor IL-10 is significantly decreased (p <0.001), and the levels of TNF-alpha, IL-6 and IL-8 are significantly decreased (p <0.001) and the level of IL-10 is significantly increased (p <0.001) after Lactobacillus rhamnosus LRa05 is dried, which indicates that Lactobacillus rhamnosus LRa05 can effectively improve the generation of intestinal inflammation.
(IV) detection of colonic oxidative stress markers:
adding appropriate amount of rat colon into physiological saline for homogenizing, centrifuging homogenized intestinal juice at 6000rpm for 10min, discarding precipitate, collecting supernatant, and detecting the levels of superoxide dismutase (SOD), Glutathione (GSH) and Malondialdehyde (MDA) by kit method.
As a result, as shown in fig. 6-8, the MDA content in IBS group was significantly increased (p <0.001) compared to the normal group, and in contrast, the MDA level in rats was significantly increased after LRa05 drying (p < 0.001). In addition, compared with the normal group, the levels of SOD and GSH in IBS group are obviously reduced (p is less than 0.001); after LRa05 dry, SOD (p <0.001) and GSH (p <0.01) levels were significantly increased. It was demonstrated that Lactobacillus rhamnosus LRa05 can relieve oxidative stress.
(V) analyzing intestinal flora:
cutting the cecum with a thin blade, scraping off the intestinal contents, weighing an appropriate amount, extracting the total DNA of the intestinal flora by a kit method, and analyzing the change of the flora structure among the groups by using a metagenome sequence. As a result, as shown in FIG. 9, the structural change of the colonies among the groups at the phylum level was analyzed, and the numbers of Firmicutes and bacteroidetes (Bacteroides) in the IBS group were decreased as compared with the normal group; the number of Proteobacteria (Proteobacteria) and Actinomycetes (Actinobacillus) is increased, and the increase of the number of the bacteria promotes the growth of more pathogenic bacteria, so that the intestinal flora is disturbed; the number of Firmicutes and bacteroidetes increases after the intervention of Lactobacillus rhamnosus LRa 05; the number of Proteobacteria (Proteobacteria) and Actinomycetes (Actinobacillus) is reduced, and the results prove that the Lactobacillus rhamnosus LRa05 can effectively regulate the normal dysbacteriosis of intestinal tracts.
Examples 2 to 6
Examples 2-6 provide five solid beverages containing lactobacillus rhamnosus LRa05 at different content formulations, the formulations of which are specifically shown in table 2 below:
TABLE 2
The preparation method of the solid beverage comprises the following steps:
respectively mixing the freeze-dried powder containing the lactobacillus rhamnosus LRa05, fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomaltose oligosaccharide and inulin for 30min at 25 ℃ at a rotating speed of 20r/min according to the proportion, and then uniformly mixing to obtain the solid beverage containing the lactobacillus rhamnosus LRa 05.
Comparative examples 1 to 6
Comparative examples 1 to 6 provide five solid beverages containing lactobacillus rhamnosus LRa05 with different content formulations, the preparation method is the same as the examples, and the formulations of the solid beverages are specifically shown in the following table 3:
TABLE 3
Comparative example 7
The comparative example provides a lactobacillus rhamnosus-containing solid beverage, which is different from the solid beverage prepared in example 2 in that the lactobacillus rhamnosus LRa 05-containing freeze-dried powder is replaced by lactobacillus rhamnosus freeze-dried powder with the accession number of CNCM I-3990 in equal mass (the freeze-dried powder is prepared by the same method as the preparation examples, and only the lactobacillus rhamnosus LRa05 is replaced by lactobacillus rhamnosus with the accession number of CNCM I-3990).
Comparative example 8
The comparative example provides a solid beverage containing lactobacillus rhamnosus, and the difference from the example 2 is that the freeze-dried powder containing lactobacillus rhamnosus LRa05 is replaced by the composite freeze-dried powder with equal mass;
the preparation method of the freeze-dried powder is the same as that of the preparation example, and the differences are only that: the single lactobacillus rhamnosus LRa05 was replaced by the following groups of bacteria: 5% of Lactobacillus acidophilus (accession number CNCM I-4099), 80% of Lactobacillus casei (CNCM I-3989) and about 15% of Lactobacillus rhamnosus (accession number CNCM I-3990).
Test example 1
Study on the improvement effect of solid beverage containing Lactobacillus rhamnosus on IBS
Firstly, constructing an animal model: the animal early-stage feeding is the same as example 1, 150 SD rats are evenly divided into a normal group, an IBS group, an example 2-6 group and a comparative example 1-8 group according to the physical and physical states, each group comprises 10 rats, an animal model is constructed on the IBS group, the example 2-6 group and the comparative example 1-8 group by adopting a chemical stimulation method, the method is the same as example 1, and then solid beverage intervention with different formulas and different doses is carried out on the example 2-6 group and the comparative example 1-8 group respectively, and the method comprises the following steps: the solid beverage was dissolved in physiological saline to prepare a solid beverage solution, and normal group and IBS group were administered with physiological saline (0.1mL/10 g).
(II) general condition checking:
observing the overall states of the rats before and after model building and beverage groups intervene, such as drinking water, diet, body mass, stool, death and the like, calculating Disease Activity Index (DAI), and specifically testing results are shown in the following table 4:
TABLE 4
From the results in table 4, it can be seen that the solid beverage prepared from the lyophilized powder of Lactobacillus rhamnosus LRa05 provided by the present invention has significant efficacy on irritable bowel syndrome.
Among them, as can be seen from the comparison between example 2 and comparative examples 1 to 6, the prebiotics fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomaltose oligosaccharide and inulin are mutually matched, so that the prebiotics fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomaltose oligosaccharide and inulin have a synergistic effect, can promote the Lactobacillus rhamnosus (Lactobacillus rhamnosus) LRa05 to proliferate in intestinal tracts, and the combination of the prebiotics fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomaltose oligosaccharide and inulin with Lactobacillus rhamnosus (Lactobacillus rhamnosus) LRa05 improves the colonization rate and the survival rate of exogenous probiotics on intestinal tracts, so that the prebiotics has a more excellent IBS improving effect. As can be seen from comparison between the example 2 and the comparative examples 7-8, compared with the beverage prepared from single lactobacillus rhamnosus or the compound bacteria provided by the example 7, the lactobacillus rhamnosus LRa05 with the preservation number of CGMCC No.1.12734 provided by the invention has more excellent IBS improving efficacy.
Test example 2
Clinical trial
The relieving effect of the solid beverages provided in examples 2 to 6 and comparative examples 1 to 8 on constipation-predominant irritable bowel syndrome was evaluated. 130 volunteers with constipation-predominant irritable bowel syndrome (inclusion standard: corresponding to the diagnosis standard related to irritable bowel syndrome in western medicine and Chinese medicine theory and confirmed diagnosis; all volunteers have typical manifestations of constipation-predominant irritable bowel syndrome; no allergic history to solid beverages; understanding test contents and agreeing to participate in the test; exclusion standard: the volunteers have been treated with other drugs before the test is started; cardiovascular diseases, renal diseases and other organic diseases) are randomly divided into 13 groups, and 10 volunteers take 10g of the solid beverages provided in examples 2-6 and comparative examples 1-8 every day. All volunteers had a uniform drinking time after breakfast and received a uniform regular diet regimen during the trial period, including adjustment of diet structure, increase of dietary salty taste and water intake, etc., and no other drugs for gastrointestinal diseases and other fermented foods, and the trial period was 6 months.
And (3) evaluating the curative effect: the constipation symptoms and the stool characteristics of the volunteers before and after taking the solid beverage are observed, the constipation symptom score refers to a constipation symptom score table of the anorectal surgery group of the Chinese medical society, evaluation is carried out through 6 items of difficult defecation, stool characteristics (BSS), defecation time, feeling of incomplete falling and swelling, frequency and abdominal distension, the score is set to be 0-3, the higher the score is, the more serious the symptoms are, and the score is averaged before and after the volunteer experiment. The symptom scores for abdominal distension, abdominal pain and difficulty defecation before and after the test are listed in table 5 for each group of volunteers.
The specific test results are shown in table 5 below:
TABLE 5
The results show that: as can be seen from the data in table 5, the solid beverages provided in examples 2 to 4 significantly improved the symptoms of abdominal distension, abdominal pain, and difficulty in defecation, and thus the solid beverages provided in examples 2 to 4 demonstrated significant effects of relieving constipation-predominant irritable bowel syndrome.
Among them, as can be seen from the comparison between example 2 and comparative examples 1 to 6, the prebiotics fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomaltose oligosaccharide and inulin are mutually matched, so that the prebiotics fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomaltose oligosaccharide and inulin have a synergistic effect, can promote the Lactobacillus rhamnosus (Lactobacillus rhamnosus) LRa05 to proliferate in intestinal tracts, and the combination of the prebiotics fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomaltose oligosaccharide and inulin with Lactobacillus rhamnosus (Lactobacillus rhamnosus) LRa05 improves the colonization rate and the survival rate of exogenous probiotics on intestinal tracts, so that the prebiotics has a more excellent IBS improving effect. As can be seen from the comparison between the example 2 and the comparative examples 7-8, the Lactobacillus rhamnosus LRa05 with the preservation number of CGMCC No.1.12734 provided by the invention has more excellent IBS improving effect compared with the beverage prepared by the single Lactobacillus rhamnosus provided by the example 7 or the compound bacteria provided by the example 8.
The applicant states that the present invention is illustrated by the above examples of the application of lactobacillus rhamnosus LRa05 of the present invention in the preparation of a preparation for improving irritable bowel syndrome, but the present invention is not limited to the above process steps, i.e. it does not mean that the present invention must rely on the above process steps for its implementation. It will be apparent to those skilled in the art that any modification of the present invention, equivalent substitutions of selected materials and additions of auxiliary components, selection of specific modes and the like, which are within the scope and disclosure of the present invention, are contemplated by the present invention.
Claims (10)
1. An application of Lactobacillus rhamnosus LRa05 in preparing preparation for improving irritable bowel syndrome;
the Lactobacillus rhamnosus LRa05 is Lactobacillus rhamnosus LRa05, is preserved in China general microbiological culture Collection center (CGMCC), the preservation time is 2020, 7 and 20 days, the preservation number is CGMCC No.1.12734, and the address is as follows: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North.
2. Use according to claim 1, wherein the formulation comprises an oral medicament and/or food.
3. The use of claim 2, wherein the oral medicament is in the form of suppository, powder, capsule, powder, solution, emulsion, enema, gel or tablet;
preferably, the food comprises any one of solid beverage, fermented milk or fermented fruit and vegetable or a combination of at least two of the two.
4. A solid beverage containing Lactobacillus rhamnosus LRa05 is characterized by comprising the following components: freeze-dried powder containing lactobacillus rhamnosus LRa05, fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomalto-oligosaccharide and inulin.
5. The solid beverage containing lactobacillus rhamnosus LRa05, according to claim 4, wherein the solid beverage containing lactobacillus rhamnosus LRa05 comprises the following components in parts by weight: 0.1-10 parts of freeze-dried powder containing lactobacillus rhamnosus LRa05, 10-20 parts of fructo-oligosaccharide, 10-20 parts of xylo-oligosaccharide, 10-15 parts of galacto-oligosaccharide, 10-15 parts of isomalto-oligosaccharide and 10-20 parts of inulin.
6. The solid beverage containing Lactobacillus rhamnosus LRa05 of claim 4 or 5, wherein the viable count of the lyophilized powder containing Lactobacillus rhamnosus LRa05 is (1-3) x 1011CFU/g。
7. The solid beverage containing lactobacillus rhamnosus LRa05 of any one of claims 4-6, wherein the lyophilized powder containing lactobacillus rhamnosus LRa05 is prepared by the following preparation method:
(a) activating the strain of lactobacillus rhamnosus LRa05, culturing, and collecting thallus;
(b) and (b) mixing the thallus obtained in the step (a) with a protective agent, and freeze-drying to obtain the freeze-dried powder containing the lactobacillus rhamnosus LRa 05.
8. The solid beverage containing lactobacillus rhamnosus LRa05 of claim 7, wherein in step (a), the specific steps of the activation are: inoculating lactobacillus rhamnosus LRa05 in MRS liquid culture medium, standing for culture, and activating for 2 generations;
preferably, the inoculation amount of the lactobacillus rhamnosus LRa05 is 1-3 wt%;
preferably, the temperature of the static culture is 32-37 ℃, and the time of the static culture is 16-20 h;
preferably, in step (a), the cultivation comprises the following specific steps: inoculating the activated seeds into a fermentation tank, and culturing to obtain a bacterial liquid;
preferably, the amount of inoculated seeds after activation is 1-3 wt%;
preferably, the temperature of the culture is 32-37 ℃, and the time of the culture is 10-15 h;
preferably, the pH of the bacterial liquid to be controlled in the culture is 5.5-6.5;
preferably, in the step (a), the step of collecting the bacterial cells comprises the following specific steps: centrifuging the bacterial liquid, removing supernatant, and collecting bacterial mud;
preferably, the rotation speed of the centrifugation is 6000-;
preferably, in the step (b), the mass ratio of the thallus to the protective agent is (0.5-2) to 1;
preferably, the protective agent consists of trehalose, maltodextrin and sucrose;
preferably, the mass ratio of the trehalose to the maltodextrin to the sucrose is (20-30): (5-15): (1-3).
9. Method for preparing a solid beverage containing lactobacillus rhamnosus LRa05 according to any of claims 4-8, characterized in that the preparation method comprises the following steps:
and mixing the freeze-dried powder containing the lactobacillus rhamnosus LRa05, fructo-oligosaccharide, xylo-oligosaccharide, galacto-oligosaccharide, isomalto-oligosaccharide and inulin to obtain the solid beverage containing the lactobacillus rhamnosus LRa 05.
10. The method for preparing a solid beverage containing lactobacillus rhamnosus LRa05 of claim 9, wherein the rotation speed of the mixing is 10-30r/min, the temperature of the mixing is 20-30 ℃, and the time of the mixing is 20-40 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210408975.2A CN114766677A (en) | 2022-04-19 | 2022-04-19 | Application of lactobacillus rhamnosus LRa05 in preparing preparation for improving irritable bowel syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210408975.2A CN114766677A (en) | 2022-04-19 | 2022-04-19 | Application of lactobacillus rhamnosus LRa05 in preparing preparation for improving irritable bowel syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114766677A true CN114766677A (en) | 2022-07-22 |
Family
ID=82430715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210408975.2A Pending CN114766677A (en) | 2022-04-19 | 2022-04-19 | Application of lactobacillus rhamnosus LRa05 in preparing preparation for improving irritable bowel syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114766677A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114711430A (en) * | 2022-03-31 | 2022-07-08 | 杭州曼士元食品科技有限公司 | Food composition preparation for resisting helicobacter pylori |
| CN116508993A (en) * | 2023-03-21 | 2023-08-01 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus reuteri in preparation of probiotics with metabolism regulating effect |
| CN117586927A (en) * | 2024-01-18 | 2024-02-23 | 山东中科嘉亿生物工程有限公司 | Lactobacillus rhamnosus JYLR-127 for improving difficult defecation after fracture, microbial inoculum and application thereof |
| CN117844713A (en) * | 2024-03-04 | 2024-04-09 | 微康益生菌(苏州)股份有限公司 | Composite probiotics for improving immunity and application thereof |
| CN117987327A (en) * | 2024-04-02 | 2024-05-07 | 微康益生菌(苏州)股份有限公司 | Compound probiotics for resisting hepatitis B virus and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112210507A (en) * | 2020-08-10 | 2021-01-12 | 江苏微康生物科技有限公司 | Shigella-antagonistic lactobacillus rhamnosus LRa05, screening method and application thereof |
| CN112654358A (en) * | 2018-03-05 | 2021-04-13 | 生物K+国际公司 | Lactobacillus combination for relieving irritable bowel syndrome and for relieving other gastrointestinal diseases |
| CN113430133A (en) * | 2021-06-24 | 2021-09-24 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
-
2022
- 2022-04-19 CN CN202210408975.2A patent/CN114766677A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112654358A (en) * | 2018-03-05 | 2021-04-13 | 生物K+国际公司 | Lactobacillus combination for relieving irritable bowel syndrome and for relieving other gastrointestinal diseases |
| CN112210507A (en) * | 2020-08-10 | 2021-01-12 | 江苏微康生物科技有限公司 | Shigella-antagonistic lactobacillus rhamnosus LRa05, screening method and application thereof |
| CN113430133A (en) * | 2021-06-24 | 2021-09-24 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114711430A (en) * | 2022-03-31 | 2022-07-08 | 杭州曼士元食品科技有限公司 | Food composition preparation for resisting helicobacter pylori |
| CN116508993A (en) * | 2023-03-21 | 2023-08-01 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus reuteri in preparation of probiotics with metabolism regulating effect |
| CN116508993B (en) * | 2023-03-21 | 2023-12-15 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus reuteri in preparation of probiotics with metabolism regulating effect |
| CN117586927A (en) * | 2024-01-18 | 2024-02-23 | 山东中科嘉亿生物工程有限公司 | Lactobacillus rhamnosus JYLR-127 for improving difficult defecation after fracture, microbial inoculum and application thereof |
| CN117586927B (en) * | 2024-01-18 | 2024-04-23 | 山东中科嘉亿生物工程有限公司 | Lactobacillus rhamnosus JYLR-127 for improving difficult defecation after fracture, microbial inoculum and application thereof |
| CN117844713A (en) * | 2024-03-04 | 2024-04-09 | 微康益生菌(苏州)股份有限公司 | Composite probiotics for improving immunity and application thereof |
| CN117844713B (en) * | 2024-03-04 | 2024-05-14 | 微康益生菌(苏州)股份有限公司 | Composite probiotics for improving immunity and application thereof |
| CN117987327A (en) * | 2024-04-02 | 2024-05-07 | 微康益生菌(苏州)股份有限公司 | Compound probiotics for resisting hepatitis B virus and application thereof |
| CN117987327B (en) * | 2024-04-02 | 2024-06-07 | 微康益生菌(苏州)股份有限公司 | Compound probiotics for resisting hepatitis B virus and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114766677A (en) | Application of lactobacillus rhamnosus LRa05 in preparing preparation for improving irritable bowel syndrome | |
| CN107523526B (en) | Lactobacillus reuteri and application thereof | |
| CN110150669B (en) | Probiotic composition suitable for diabetic patients and application thereof | |
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| CN112501046B (en) | Lactobacillus fermentum with weight-losing function and application thereof | |
| CN113855712B (en) | Composition capable of promoting defecation and application thereof | |
| CN109125525B (en) | Composition for preventing and treating cardiovascular diseases and preparation method and application thereof | |
| CN116286551B (en) | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity | |
| CN111329884B (en) | Application of lactobacillus plantarum BC299 in medicines and foods for treating inflammatory bowel diseases and psychogenic problems | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| CN116121154B (en) | Leuconostoc lactis and application thereof | |
| US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
| CN114558036A (en) | Application of bacteroides fragilis in improvement and treatment of diarrhea | |
| CN114045233A (en) | Direct-vat-set fermentation inoculant for relieving constipation-predominant irritable bowel syndrome and preparation method and application thereof | |
| WO2020006663A1 (en) | Novel lactobacillus paracasei gks6 for mitigating metabolic syndrome, culture medium thereof, culture method, use, pharmaceutical composition, and edible composition | |
| CN114145461B (en) | Probiotic composition for relieving nonalcoholic fatty liver | |
| CN114452308A (en) | Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent | |
| CN109965290B (en) | Meal replacement powder for improving intestinal flora and application thereof | |
| CN105343132B (en) | Composition, the drug and preparation method thereof for treating colitis | |
| CN105707898A (en) | Toxin removing and bowel relaxing probiotic composition and preparation method and application thereof | |
| CN117838736B (en) | Application of bacillus coagulans JA845 in preparation of medicines for preventing and/or treating atherosclerosis | |
| CN117981875B (en) | Lactobacillus reuteri Gly LR15 composition with immunity improving function and preparation method thereof | |
| CN114404459B (en) | Application of lactobacillus reuteri CCFM1135 in reducing plasma trimethylamine oxide | |
| CN117946949B (en) | Acremonium muciniphilum and application thereof | |
| Marsaid et al. | The Effectiveness Of Administering Oral Honey Against The Degree Of Dehydration In Children With Acute Diarrhea In Malang, Indonesia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |